Prostate cancer focal therapy: surgeon experience influences oncological results
The Prostate · 2025
DOI: 10.1002/pros.24800 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Prostate, 2025. Verfasst von Claudio Bovolenta Murta und 8 weiteren Autor:innen. Beteiligte Einrichtung: Urology Department, Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil. Hauptthemen laut MEDLINE: Prostatic Neoplasms. Die Arbeit nennt 14 Literaturangaben.
Abstract (Originalsprache)
Introduction
Characterization of the index lesion of prostate cancer (PCa) has facilitated the development of focal therapy to reduce complications caused by radical treatments. In the present study, we sought to identify factors associated with the oncological results of focal therapy for PCa.
Methods
Between April 2017 and February 2020, 123 PCa patients received focal therapy performed with high‐intensity focused ultrasound (HIFU). The patients presented unilateral localized disease, PSA < 20 ng/dl, clinical stage T1–T2, ISUP grade 1–3, and more than 10 years of life expectancy. Five certified surgeons with different levels of experience performed the procedures and were divided into groups #1 and #2 (>30 HIFUs performed) and #3 (10–15 HIFUs performed each). All patients were prospectively followed and underwent surveillance biopsy 1 year post‐treatment. The primary endpoint was radical treatment, and secondary endpoints included focal therapy failure and in‐field recurrence. Univariate and multivariate logistic regression were used to detect associations between clinical and procedure variables and the endpoints.
Results
The median follow‐up was 54.3 months, with a mean age of 64.4 years. The mean PSA was 6.6 ng/dl; 59.3% of patients had intermediate‐risk disease, and the remaining had low‐risk. During follow‐up, 29 (23.6%) patients required radical treatment (external beam radiation therapy), 37 (30.1%) experienced treatment failure, and 26 (21.1%) had an in‐field recurrence with an ISUP grade of ≥2. Radical treatment in the follow‐up was associated with patients treated by surgeons in group #3 and with elevated post‐HIFU PSA concentrations. Baseline PSA concentrations, group #3 surgeons, and post‐HIFU PSA concentrations were associated with treatment failure. In‐field positive biopsies were associated with baseline and post‐HIFU PSA concentrations. Furthermore, patients treated by surgeons in group #3 were independently associated with radical treatment and focal therapy failure.
Conclusion
Focal therapy with HIFU has acceptable oncological outcomes in the medium term, and the surgeon's experience and technique are independently associated with the need for subsequent radical treatment and focal therapy failure.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Urology Department, Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil.
- Division of Urology, Men's Health Centre, Hospital Brigadeiro, São Paulo, Brazil.
ORCID-Profile: Claudio Bovolenta Murta
Zitieren
APA
Murta, C. B., Júnior, J. P., de Souza Filho, P. H. F., de Godoy Júnior, P. C., Pugliesi, F. G., El Hayek, K. R., Gallucci, F. P., Guglielmetti, G. B., & de Almeida Claro, J. F. (2025). Prostate cancer focal therapy: surgeon experience influences oncological results. The Prostate. https://doi.org/10.1002/pros.24800
Vancouver
Murta CB, Júnior JP, de Souza Filho PHF, de Godoy Júnior PC, Pugliesi FG, El Hayek KR, et al. Prostate cancer focal therapy: surgeon experience influences oncological results. The Prostate. 2025. doi:10.1002/pros.24800
BibTeX
@article{Murta2025,
author = {Murta, Claudio Bovolenta and Júnior, José Pontes and de Souza Filho, Pedro Humberto Felix and de Godoy Júnior, Paulo Cezar and Pugliesi, Felipe Guimarães and El Hayek, Kayann Reda and Gallucci, Fábio Pescarmona and Guglielmetti, Giuliano Betoni and de Almeida Claro, Joaquim Francisco},
title = {Prostate cancer focal therapy: surgeon experience influences oncological results},
journal = {The Prostate},
year = {2025},
doi = {10.1002/pros.24800}
}
EUVIMED